2005

A new adhesive method using an adhesive composition including cyanoacrylate adhesive and a stabilizing agent to join together portions of a substrate, particularly useful in suturing and similar medical procedures, is disclosed.

Disclosed are methods and formulations for the treatment or prevention of infections on mammalian tissues such as skin. Specifically, the methods of this invention involve the in situ formation of a polymeric cyanoacrylate film containing mixed antibiotics over mammalian tissue.

A cyanoacrylate composition comprising (i) at least one lower cyanoacrylate monomer component selected from ethyl cyanoacrylate or methoxy ethylcyanoacrylate; (ii) at least one higher cyanoacrylate monomer component than in an amount greater than 12% by weight based on the total weight of the combination of the lower cyanoacrylate monomer and the higher cyanoacrylate monomer and (iii) a plasticizer. The higher cyanoacrylate monomer and the plasticizer are chosen from certain ones. The compositions cure to give flexible polymeric materials which are desirably also transparent.

A package assembly or kit can be used in conjunction with storing and dispensing adhesive materials. The package assembly can include an enclosure in which an applicator and a container may be positioned. The container contains adhesive material. The enclosure may include a base and a cover. The base preferably includes one or more cavities, with at least one applicator disposed in one of the cavities. Further, the container may be disposed in another of the cavities. The cover may be provided with a plurality of wells.

This CICAD on methyl cyanoacrylate and ethyl cyanoacrylate was based on a review of human health concerns (primarily occupational) prepared by the United Kingdom’s Health and Safety Executive (HSE) (Cary et al., 2000). Hence, this document focuses on exposures via routes relevant to occupational settings. Data identified as of September 1999 were covered. A further literature search was performed up to February 2000 to identify any extra information published since this review was completed.

This highlight is about my metamorphosis from a cationic polymerization chemist to a biomaterialist (no pun intended) and some of the main events on the road. My earlier career faded away with the discovery of living cationic polymerizations, chronicled in my 1999 highlight, but it also put me on the road to designed biomaterials.

Cyanoacrylates (CAs) were not widely adopted for medical use until recently because of lingering concerns regarding the initial tissue toxicities of the short-chain CAs. The medium-chain CAs, primarily butyl-cyanoacrylate, have been widely used in Europe and Canada for several decades and have gone a long way in dispelling any lingering concerns about tissue toxicity. The newer, longer chain CA,octyl-2-cyanoacrylate (2-OCA), now has been approved for multiple uses in the United States and has achieved widespread acceptance by the medical and lay communities.

Cyanoacrylates (CAs) were not widely adopted for medical use until recently because of lingering concerns regarding the initial tissue toxicities of the short-chain CAs. The medium-chain CAs, primarily butyl-cyanoacrylate, have been widely used in Europe and Canada for several decades and have gone a long way in dispelling any lingering concerns about tissue toxicity. The newer, longer chain CA, octyl-2-cyanoacrylate (2-OCA), now has been approved for multiple uses in the United States and has achieved widespread acceptance by the medical and lay communities.